Non-Alcoholic Steatohepatitis (NASH) Drugs Market Report

Global and Region Non-Alcoholic Steatohepatitis (NASH) Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：200
  • REPORT CODE：GMM962248
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Non-Alcoholic Steatohepatitis (NASH) Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Non-Alcoholic Steatohepatitis (NASH) Drugsmarket, defines the market attractiveness level of Non-Alcoholic Steatohepatitis (NASH) Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Non-Alcoholic Steatohepatitis (NASH) Drugs industry, describes the types of Non-Alcoholic Steatohepatitis (NASH) Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market and the development prospects and opportunities of Non-Alcoholic Steatohepatitis (NASH) Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) Drugs market in Chapter 13.

    By Player:

    • Intercept Pharmaceuticals

    • Immuron

    • Genfit

    • Galmed Pharmaceuticals

    • Novo Nordisk

    • AstraZeneca

    • Horizon Pharma

    • Conatus Pharmaceuticals

    • Enzo Biochem

    • Gilead

    By Type:

    • Vitamin E & Pioglitazone

    • Obeticholic Acid (OCA)

    • Elafibranor

    • Selonsertib & Cenicriviroc

    By End-User:

    • Hospital Pharmacy

    • Online Provider

    • Retail Pharmacy

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Non-Alcoholic Steatohepatitis (NASH) Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)

    • 7.2 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)

    • 7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)

    • 7.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)

    • 7.5 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)

    • 7.6 India Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)

    • 7.7 South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption (2017-2022)

    8 Region and Country-wise Non-Alcoholic Steatohepatitis (NASH) Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)

    • 8.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)

    • 8.6 India Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast (2022-2028)

    9 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Vitamin E & Pioglitazone Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Obeticholic Acid (OCA) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Elafibranor Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Selonsertib & Cenicriviroc Consumption and Growth Rate (2017-2022)

    • 9.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Online Provider Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Retail Pharmacy Consumption and Growth Rate (2017-2022)

    10 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Vitamin E & Pioglitazone Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Obeticholic Acid (OCA) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Elafibranor Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Selonsertib & Cenicriviroc Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Online Provider Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    11 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Competitive Analysis

    • 14.1 Intercept Pharmaceuticals

      • 14.1.1 Intercept Pharmaceuticals Company Details

      • 14.1.2 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.2 Immuron

      • 14.2.1 Immuron Company Details

      • 14.2.2 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.3 Genfit

      • 14.3.1 Genfit Company Details

      • 14.3.2 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.4 Galmed Pharmaceuticals

      • 14.4.1 Galmed Pharmaceuticals Company Details

      • 14.4.2 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.5 Novo Nordisk

      • 14.5.1 Novo Nordisk Company Details

      • 14.5.2 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.6 AstraZeneca

      • 14.6.1 AstraZeneca Company Details

      • 14.6.2 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.7 Horizon Pharma

      • 14.7.1 Horizon Pharma Company Details

      • 14.7.2 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.8 Conatus Pharmaceuticals

      • 14.8.1 Conatus Pharmaceuticals Company Details

      • 14.8.2 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.9 Enzo Biochem

      • 14.9.1 Enzo Biochem Company Details

      • 14.9.2 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • 14.10 Gilead

      • 14.10.1 Gilead Company Details

      • 14.10.2 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Non-Alcoholic Steatohepatitis (NASH) Drugs

    • Figure Non-Alcoholic Steatohepatitis (NASH) Drugs Picture

    • Table Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption by Country (2017-2022)

    • Figure United States Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Vitamin E & Pioglitazone Consumption and Growth Rate (2017-2022)

    • Figure Global Obeticholic Acid (OCA) Consumption and Growth Rate (2017-2022)

    • Figure Global Elafibranor Consumption and Growth Rate (2017-2022)

    • Figure Global Selonsertib & Cenicriviroc Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)

    • Figure Global Online Provider Consumption and Growth Rate (2017-2022)

    • Figure Global Retail Pharmacy Consumption and Growth Rate (2017-2022)

    • Figure Global Vitamin E & Pioglitazone Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Obeticholic Acid (OCA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Elafibranor Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Selonsertib & Cenicriviroc Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Online Provider Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Retail Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Non-Alcoholic Steatohepatitis (NASH) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Non-Alcoholic Steatohepatitis (NASH) Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table Intercept Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table Immuron (Foundation Year, Company Profile and etc.)

    • Table Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table Genfit (Foundation Year, Company Profile and etc.)

    • Table Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table Galmed Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table Novo Nordisk (Foundation Year, Company Profile and etc.)

    • Table Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table Horizon Pharma (Foundation Year, Company Profile and etc.)

    • Table Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table Conatus Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table Enzo Biochem (Foundation Year, Company Profile and etc.)

    • Table Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service

    • Table Gilead (Foundation Year, Company Profile and etc.)

    • Table Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US